Travere Therapeutics, Inc.
Every calculator, already run for TVTX
Open the full toolkit →You have the numbers on TVTX. Get the argument.
A written report on which of these readings actually decide the outcome for Travere Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
15 analysts covering TVTXAnalyst Price Target Disagreement for Travere Therapeutics, Inc.
Wall Street's bull case implies +43% from the current price; the bear case implies -1%. A 45% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for TVTX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which ha…
TVTX — frequently asked
Is TVTX a buy right now?
Wall Street's consensus rating on Travere Therapeutics, Inc. is Strong Buy across 15 analysts, with a mean price target of $74.21 (+18% vs. the current $62.76). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is TVTX's next earnings date?
Travere Therapeutics, Inc. is next scheduled to report earnings around Oct 29, 2026. A full TVTX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Travere Therapeutics, Inc.?
Analysts covering Travere Therapeutics, Inc. (TVTX) range from a bear-case target of $62.00 to a bull-case high of $90.00, with a mean consensus target of $74.21 across 14 analysts. The spread of $28.00 (45% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Travere Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Travere Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full TVTX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Travere Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.